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Abstract
Because of disease progression and the increasing number of treatment options, patients with metastatic breast cancer
face multiple decisions over time. Our aim was to identify the multiple decisions patients with metastatic breast cancer
face in order to decide which decision aids will be developed. First, we analyzed the clinical practice guidelines to identify
decisions encountered by patients with metastatic breast cancer and healthcare professionals. Furthermore, an online
questionnaire for patients, a focus group interview with patients and interviews with healthcare professionals were
performed. In addition, we performed a systematic literature research and internet search to identify relevant decision
support tools and we assessed their quality. Finally, all results were discussed with a mixed group of eight experts,
consisting of researchers, patients and healthcare professionals and a comprehensive advice was given which decision aid
to develop. It turned out that patients with metastatic breast cancer and healthcare professionals are confronted with
eight major decision points regarding treatment and examinations during the care process. We identified four decision
aids. These tools partially overlap with some of the identified decision points. Experts advised to develop a decision aid
for patients with metastatic breast cancer that would address all mentioned decision points. We concluded patients with
metastatic breast cancer and healthcare professionals will benefit from a personalized decision aid in which all eight
major decision points are addressed. This decision aid would help patients and healthcare professionals to explore
patients’ personal values and preferences in order to make a well-informed decision.
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Introduction
The World Health Organisation reports breast cancer as
the most common cancer in women worldwide. Breast
cancer is also the principle cause of death from cancer
among women1. Metastatic breast cancer means that the
cancer has spread from the breast to a location outside the
breast and surrounding lymph nodes. Metastases occur in
bones (85%), liver (40-50%), lungs (15-25%) and brain (616%).2,3 The median survival of patients with metastatic
breast cancer is approximately two years. However,
survival can vary from several months to multiple
years.4Metastatic breast cancer is considered as a noncurable disease, but the growth of the metastases can be
controlled for months to years. Treatment is focused on
slowing disease progression, maintaining well-being and
preventing and relieving symptoms and complaints.4

Medical treatment options have increased over the last
years; different types of chemotherapy, hormone therapy,
targeted therapy and palliative procedures such as surgery
and radiotherapy are available.5,6 The treatment plan for an
individual patient will depend on tumour type, location
and size of the metastasis and/or tumour, treatment
history, co-morbidity, age and health of the patient and on
the patient’s personal preferences and values.4
Because of disease progression and the increasing number
of treatment options, patients with metastatic breast
cancer face multiple decisions over time. For example,
decisions about treatments with similar or unclear
outcomes, treatments with different procedures and
potential complications. Furthermore, they also have to
decide whether or not to undergo examinations that offer
little or no new insights in disease progression. Ideally,
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these decisions should be made after patients have
received enough information to make an informed choice
and after patients’ personal values and preferences have
been shared in partnership with the caregiver(s).7 In this
process of shared decision making, healthcare
professionals and patients share the best available evidence
and healthcare professionals support patients to consider
options, to deliberate and express their preferences in
order to achieve an informed decision.8,9
Decision support tools - such as decision aids and option
grids - facilitate the process of shared decision making.
These tools can take many different forms and vary in
content and level of complexity.10 The effect of decision
aids is shown by a systematic review of 86 randomized
trials. When patients use decision aids, they improve their
knowledge of the options, feel more informed and more
clear about what matters most to them, have more realistic
expectations of benefits and harms of the options and
participate more actively in decision making. Moreover,
decision aids help patients to feel more satisfied with their
decisions and, in many situations, informed patients elect
for more conservative treatment options.10 Despite the
obvious beneficial effects of decision aids for patients,
there is limited decision support available for patients with
metastatic breast cancer. There has been a plea for
decision aids that have been developed by means of a welldocumented and systematically applied development
process, have been user-tested and are open to scrutiny.11
Our aim was to identify the multiple decisions patients
with metastatic breast cancer face in order to decide which
decision aids to develop. To achieve this, our study
focused on the following three questions:
1. Which preference-sensitive decisions do patients with
metastatic breast cancer and healthcare professionals
encounter during the care process?
2. Which decision support tools are available for patients
with metastatic breast cancer and what is their quality?
3. Which decision aid(s) should be developed?

Methods

1. Which preference-sensitive decisions do patients
with metastatic breast cancer and healthcare
professionals encounter during the care process?

To identify preference-sensitive decisions encountered by
patients with metastatic breast cancer and healthcare
professionals, we studied the care process and analysed the
clinical practice guidelines on breast cancer and metastatic
breast cancer12-15 by using the ‘HARING tool-8’
(http://www.ha-ring.nl/en/tool-8).16 This is a tool which
aims to support the integration of shared decision making
into the development to clinical practice guidelines.
Furthermore, we performed an online questionnaire for
patients, a focus group interview with patients and
individual interviews with healthcare professionals.
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Online questionnaire

Patients were approached via the online forum of the
Dutch Breast Cancer Association (B-force) to gather
information on their experiences with preference-sensitive
decision points in the care process. Patients were asked to
describe which important decision points they had faced,
their experiences with these decision points, whether and
what treatment options they were given and how the
consequences of these options were discussed with them.
The questionnaire was online for four weeks and a
qualitative thematic analysis17 by three team members was
performed to categorize important decision points.

Focus group interview

A focus group interview with patients was organized:
patients were selected from the sixty-nine patients that
responded to the online questionnaire. Selection criteria of
patients for the interview were ‘willingness to participate’
and ‘diversity in decision points’. Fifteen patients were
invited, nine participated. The focus group interview lasted
90 minutes and was moderated by two team members.
Patients were asked to elaborate on their experiences with
the important decision points identified from the online
questionnaire and with additional decision points that were
raised during the focus group. Furthermore, they were
asked which values were important for their decision
making process. The focus group was audio recorded.
Again a qualitative thematic analysis of the results was
performed by the project team. The summary of the focus
group meeting was crosschecked with all participating
patients.

Interviews with healthcare professionals

Two medical oncologists were interviewed by two
members of the project team in order to assess what
preference sensitive decision points they experience in the
treatment of patients with metastatic breast cancer. The
topic list for the interview was based on collected
information on the care process and treatment options
from guidelines, literature and the patient association. The
medical oncologists were asked questions about their
experiences with shared decision making, decision points,
use of decision aids, patient values, the healthcare process
and treatment guidelines. Both interviews were audio
recorded and transcribed verbatim. Two researchers
independently performed a qualitative thematic analysis.
Themes were allocated to all important fragments of the
transcript. Results were cross-checked with the oncologists
and frequently occurring themes were selected.

2. Which decision support tools are available for

patients with metastatic breast cancer and what is
their quality?

We performed a systematic literature and internet search
to identify decision support tools for patients with
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metastatic breast cancer and we assessed their quality and
usefulness.

Consensus was searched for and unanimously one advice
on what decision aid should be developed was formulated.

Figure 1. PICO strategy
PICO
 Population
 Intervention



Comparison
Outcome

Definition
 Patients with metastatic or advanced breast cancer, male and female, and of all ages
 Decision aids or decision supportive tools or decision support or shared decision
making
 Usual care
 All reported outcome measures for shared decision making

Systematic literature and internet search

In order to identify existing decision support tools for
patients with metastatic breast cancer, the databases
Medline, Embase and the internet were searched. The
PICO method - a common technique used in evidencebased medicine to frame and answer a clinical question was used as search strategy (Figure 1). Abstracts of
selected articles were screened for eligibility by two
researchers. Inclusion criteria were: metastatic or advanced
breast cancer, decision support tool, information on the
development, evaluation or use of the decision aid. In
addition, an internet search was performed with the same
search terms, using the snowballing method and reference
tracking: scanning the reference list of full text papers and
links to other resources and using judgment to decide
whether to pursue this further. Specific websites with an
inventory of decision aids, such as the website of the
Ottawa Hospital Research Institute (OHRI) and MedDecs were consulted.18,19 Furthermore, an international
network of experts and organisations on shared decision
making and experts on breast cancer care were contacted
to receive more specific information on articles or decision
aids.

Assessment of quality of available decision aids on
metastatic breast cancer

The quality of the decision aids was assessed by two
researchers using the International Patient Decision Aid
Standards (IPDAS) criteria.19 The IPDAS criteria are
divided into three categories: content (28 criteria),
development process (29 criteria), effectiveness (7 criteria).
If a decision aid complies with all criteria, it receives the
maximum quality score of 100%.

3. Which decision aid(s) should be developed?
All results were summarized and discussed with a mixed
team of experts: one caregiver, two patient representatives,
two experts on decision aids and shared decision making
and four researchers. Every member was asked to express
their opinion and advice on which decision aid should be
developed. Criteria for selection were ‘relevant for the
majority of patients’, ‘meeting information needs’ and
‘available information on benefits and risks of options’.
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Results
1. Which preference-sensitive decisions do patients
with metastatic breast cancer and healthcare
professionals encounter during the care process?
Clinical practice guidelines

None of the relevant clinical practice guidelines contained
explicit information on preference-sensitive decisions
during the care process.

Online questionnaire

In total, 69 patients with metastatic breast cancer
completed the online questionnaire on their experiences
with preference-sensitive decision points in the care
process. Fourteen respondents stated they did not receive
enough information from their healthcare professionals.
They missed information on the various treatment
options, medical information on the disease and the
medication (side-effects, prognosis) and options for end of
life care. Seven respondents stated they did not mind not
being able to choose; they trusted their caregiver to make
the best choice for them. Patients named seven general
categories of decision points: ‘participating in a scientific
trial’, ‘dosing schedule’ and ‘method of administration’,
‘starting a treatment’, ‘stopping a treatment’, ‘proceeding
treatment’, ‘transferring to another treatment, caregiver or
hospital’ (Figure 2). Five patients also mentioned that they
faced non-medical decisions, related to their work and
home situation.

Focus group interview

To receive more in depth information on decision points
and values involved in decision making, a focus group
interview was organized. All focus group participants
confirmed ‘starting with a treatment’, ‘dosing schedule’
and ‘method of administration’, and ‘transferring to
another caregiver’ as important medical decision points
(Figure 2). In addition, they mentioned ‘undergoing
diagnostic procedures and check-ups for monitoring’ as a
decision point. Values and preferences that are important
for decision making were related to work, social
participation, role in the family, quality of life, hobbies,
leisure, social and psychological support. Patients also state
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that they need to consider their own role in the decision
making process. Patients stated they would like to receive
support from healthcare professionals in getting insight
into their own values and preferences.

Interviews with healthcare professionals

Both oncologists had experience with shared decision
making with patients. Oncologists confirmed the following
general decision points: ‘initiating treatment’, ‘stopping
treatment’ or ‘proceeding with treatment’. Furthermore,
they mentioned ‘starting with palliative chemotherapy’,
‘proceeding to second or third line chemotherapy’,
‘stopping with third line chemotherapy’, ‘choosing
between different types of chemotherapy’ and ‘dosing
schedule’ (Figure 2). Both oncologists experienced
difficulties in the shared decision making process, since the
number of administrations for each chemotherapy is
limited to a maximum according to treatment protocols
and guidelines, which narrows down the treatment
options. According to the oncologists, most patients’
values or preferences within the deliberation process are
related to aspects of quality of life and the home and work
situation. Side-effects of a treatment, especially hair loss,
age and expectations of others are important arguments
for patients to reject a treatment.

2. Which decision support tools are available
for patients with metastatic breast cancer
and what is their quality?
To identify decision support tools for patients with
metastatic breast cancer, we performed a systematic
literature and internet search.

Systematic literature and internet search

The systematic literature search in Embase and Pubmed
resulted in 133 articles. Only papers that concerned
metastatic or advanced breast cancer, decision support
tools, information on the development, evaluation or use
of the decision aid were included. After applying the
selection criteria, three articles remained. Two of these
referred to the same decision aid. The internet search
resulted in two additional decision aids (Figure 3).
Consulting the international network of experts on shared
decision making and experts of advanced breast cancer
provided no additional relevant decision aids.

Assessment of quality of available decision aids on
metastatic breast cancer

The quality of the four decision aids was assessed with the
IPDAS criteria (Figure 2) by two independent researchers.
Decision aid number 1 (Facing a treatment decision:
Decision aid for patients with metastatic breast cancer
considering chemotherapy) scored 60.4% on 53 criteria.
The decision aid compares chemotherapy in addition to
supportive care versus supportive care alone. The quality
of the content and the effectiveness scored good (16 out
of 23 resp. 6 out of 7 criteria). However, the decision aid
does not provide any information or references regarding
the development process and therefore scores low on the
section ‘development process’ (10 out of 23 criteria). It
contains a worksheet for patients to gain insight into their
personal values and preferences. However, the decision aid
contains a lot of text and the overall readability, scored
with the SMOG criteria, is low.
The second decision aid (Living with metastatic breast
cancer: making the journey your own) scored 56.6% on 53
criteria. It gives a general description of all treatment

Figure 2. Overview of important decision points for patients with metastatic breast cancer
Decision points














Should I participate in a scientific trial?
Should I change the dosing schedule of the medication?
Should I change the method of administration of the medication?
Should I start a treatment?
Should I stop a treatment?
Should I proceed with the treatment?
Should I transfer to another treatment, caregiver or hospital?
Non-medical decisions, related to their work and home situation
Should I undergo diagnostic procedures and check-ups for monitoring?
Should I start with palliative chemotherapy?
Should I proceed to second- or third line chemotherapy?
Should I stop with third line chemotherapy?
Which type of chemotherapy do I prefer?

53

Online
questionnaire
Patients
x
x
x
x
x
x
x
x

Focusgroup
Patients

Interviews
Caregivers

x
x
x

x
x
x
x

x
x
x
x
x
x
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Figure 3. Decision aids for patients with metastatic breast cancer and the scoring on the IPDAS criteria
Decision aid

Facing a treatment decision:
Decision aid for patients with
metastatic breast cancer
considering chemotherapy
(English) Chiew et al.20
Living with metastatic breast
cancer: Making the journey your
own (English) – DartmouthHitchcock Medical Center21,22
Decision aid palliative
chemotherapy for mamma
carcinoma (Dutch) –
RadboudUMC 23
Mayoclinic: Interactive Breast
Cancer Decision Tool (English)
(http://www.mayoclinic.com) [not
available anymore]

Decision points

IPDAS criteria
Content
Development
process†

Effectiveness

Chemotherapy (yes or
no) for patients who are
resistant for hormone
therapy

16/23

10/23

6/7

Total
score
(%)
60.4

All treatment options

8/23

18/23

4/7

56.6

Chemotherapy (yes or
no)

10/23

9/20

2/7

42.0

General overview of
4/23
3/20
1/7
16.0
breast cancer regarding
for example anatomy,
stage, type and
treatment options
† Depending on the format and content of the decision aid, additional criteria were applied, causing the total number of
criteria to vary between different decision aids.
options. This tool rates high on the criteria of the
development process (18 out of 23 criteria). The decision
aid does not provide data regarding survival, side-effects
and associated risks specific for those treatment options,
or more preferably, their subtypes. This decision aid
scored sufficiently on readability, but due to the large
amount of text, overall readability might be low. This tool
provides examples of patients’ experiences with treatments
to give more insight into which personal values and
considerations are associated with the decision. However,
the decision aid does not stimulate the patient to reflect on
the meaning of this information for personal consideration
(value clarification).

shared decision making process. No information on
benefits and risks of treatment options and no checklist to
elicit values and preferences is presented.

3.

Which decision aid(s) should be developed?

The third decision aid, called palliative chemotherapy for
mamma carcinoma, scored 42.0% on 50 criteria. The
decision aid compares chemotherapy with the option of
watchful waiting and provides information on survival,
benefits and risks. However, the decision aid does not help
the patient to gain insight into their own preferences
regarding treatment options and outcomes. In addition,
the decision aid scored low on development process (9 out
of 20 criteria) and readability.

Important decision points that could be addressed in a
decision aid according to patients and oncologist are:
1. participating in a scientific trial
2. dosing schedule and method of administering
medication
3. starting a treatment, stopping or proceeding treatment
4. transferring to another treatment, caregiver or hospital
5. non-medical decisions, related to work- and home
situation
6. undergoing diagnostic procedures and check-ups for
monitoring, for example CT-scans
7. starting with palliative chemotherapy
8. changing type of, stopping or proceeding second or
third line chemotherapy (i.e. a new variant of
chemotherapy when the previous type causes for
example too may side-effects, or the disease
progresses) (Figure 2).

The fourth decision aid, a video of the Mayo Clinic
Interactive Breast Cancer Decision Tool, scored 16.0% on
50 criteria. The video gives a general overview of breast
cancer; such as anatomy, stage of disease and treatment
options. This information, however, is too general in order
to support patients and healthcare professionals in a

The existing decision aids address medical decisions; two
describe the choice between chemotherapy in addition to
supportive care versus supportive care alone, one decision
aid gives a description of all general treatment options and
the option of ‘watchful waiting’ for patients with
metastatic breast cancer and one gives a general overview
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of breast cancer, regarding for example disease stage,
anatomy and general treatment options for all stages.
Therefore, only a fraction of the mentioned decision
points is covered in these decision support tools. Finally,
after discussing all results, the project team and experts
advise to develop a decision aid for patients with
metastatic breast cancer that addresses all mentioned
decision points.

Discussion
From our study, we conclude that patients with metastatic
breast cancer and their healthcare professionals face eight
major preference-sensitive decision points during the care
process. Furthermore, since available decision aids do not
cover all these decision points, there is a need for a
decision aid that addresses all identified decision points.
Guidelines on breast cancer contain no explicit
information on the advantages and disadvantages of the
various treatment and care options for patients with
metastatic breast cancer and their healthcare professionals.
However, our study shows that patients with metastatic
breast cancer and their healthcare professionals face eight
major preference-sensitive decision points during the care
process. For some of the mentioned decision points,
decision support tools are available. However, none of the
identified decision support tools covers all eight major
decision points, due to the limited focus or the moderate
quality of the decision aids. Therefore, the project team
and experts decided to start the development of a decision
aid that addresses the eight decision points and provides a
personal value worksheet to help patients and healthcare
professionals to explore the patient’s personal preferences
and values. This decision aid will employ the relevant parts
of the identified decision aids and correspond with the
content of the Dutch guideline on breast cancer, in line
with the advice of experts.12, 24, 25
In 1995, a study by McQuellon26 emphasized that patients
have clear preferences for specific treatments for
metastatic disease. However, their preferred role in the
decision making process varies among patients. In
addition, individual patients' preferences often change in
the course of the disease. In particular, in the last phase of
life, patients often put more emphasis on weighing length
of life against quality of life. For instance, in the decision
whether or not to start treatment aimed at life
prolongation, the possibility of side effects play an
important role. Evidence suggests that informed patients
elect for more conservative treatment options associated
with more quality of life.27 Therefore, communication
about patients' expectations, wishes and preferences for
participation in treatment decisions is of great
importance.28 In our study, both patients and healthcare
professionals indicated the importance of communication
on options and values for eight major decision points.

55

In our study only two oncologists were interviewed and
only one focus group with patients was held. This resulted
in valuable qualitative data for considering the focus of the
decision aid to be developed and the information needs of
patients and their healthcare professionals. Preferably,
more interviews and multiple focus groups should be
conducted until no new answers were given (saturation).
Although both oncologists and patients mentioned
predominantly similar decision points, it might be possible
that other patients, nurses, radiologists, surgeons and
general practitioners express other decision points as well.
Another limitation is the recruitment of patients; the
patients interviewed, were contacted through the website
of the Dutch Breast Cancer Association. Patients that
responded to the questionnaire are active members within
the metastatic breast cancer community and might have a
different opinion about the major decision points than
other patients. Third, all participants of the focus group
were diagnosed with earlier stage breast cancer several
years before receiving the diagnosis of metastatic breast
cancer. There were no patients who did not have any
history with early stage breast cancer in the focus group.
Results of the focus group therefore might not completely
reflect all decisions patients within the whole community
of metastatic breast cancer face after diagnosis. Despite
these limitations, this is the first study to give insight into
the major decision points patients with metastatic breast
cancer and healthcare professionals are facing during the
care process. It is also one of the fewer studies that
comprehensively describes the process of starting the
development of a decision aid.
This explorative study provides useful results which can be
used in further research or the development of a decision
aid for patients with metastatic breast cancer. Both
patients and healthcare professionals were interviewed to
obtain more in-depth knowledge about the decision points
that patients with metastatic breast cancer encounter.
Their responses and the analysis of available decision aids
showed that there is a strong need for the development of
a decision tool to support the decision making process
relating to eight different decision points, in which the
patient’s values and preferences are taking into account as
well.
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